Magellan Rx Management issues seventh Medicaid Pharmacy Trend Report™

Features new highlights and rankings of the top 50 drug classes by percent of net spend

January 25, 2023
Prime Therapeutics and Magellan RX Management Banner

EAGAN, Minn. – Jan. 25, 2023 –  Magellan Rx Management (Magellan Rx), a Prime Therapeutics LLC company, released its seventh annual Medicaid Pharmacy Trend Report™, the industry report detailing trends in the Medicaid pharmacy fee-for-service (FFS) space. The Medicaid Pharmacy Trend Report highlights the evolving landscape of the Medicaid FFS segment and is a detailed industry source for the analysis of gross, net, and forecasted drug cost trends in the space. This year’s report tracks the top classes and individual drugs by spend, with a deep dive into the top 10 classes driving trend and their resulting impact on the Medicaid program. New this year, the report ranked the top 50 classes by percent of net spend comparing 2020 to 2021.

“As the nation emerges from intense management of COVID-19, states and Medicaid agencies will again focus their efforts on other pressing issues in the coming years, including paying for curative therapies and high-cost drugs, addressing the opioid epidemic and challenges with mental health resources,” said Meredith Delk, PhD, MSW, general manager and senior vice president, state government solutions for Magellan Rx. “In 2021, states continued to explore and implement efforts to counterbalance the increasing cost of specialty drugs with unique payment models, including subscription and outcomes-based contracting models.”

The Medicaid Pharmacy Trend Report includes data from Magellan Rx’s Medicaid FFS pharmacy programs in 24 states and the District of Columbia. The material is reviewed and supported by a team of Magellan Rx experts with broad national expertise in Medicaid and pharmacy benefit management (PBM). Magellan Rx has more than 40 years of Medicaid-focused experience and administers pharmacy programs for Medicaid agencies of all sizes. Magellan Rx tailors services to meet the specific needs of each unique Medicaid population to improve clinical outcomes and help ensure coordination of care. One of its innovative solutions, MRx Value Plus, offers value-based contracting in the Medicaid space to positively impact total cost of care on behalf of Medicaid programs.

Related news

Press releases

April 11, 2024

Prime Therapeutics and Magellan Rx to present eight managed care pharmacy research studies at AMCP

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting

Press releases

March 13, 2024

Prime Therapeutics and Capital Rx Enter Into Transformative Strategic Alliance

Strategic alliance allows Prime to offer exclusive access to Capital Rx’s leading technology platform to achieve a higher standard of care, increase efficiency, improve experiences and provide the foundation for the next generation of integrated pharmacy care for the more than 50 million Americans served by Prime

Press releases

February 8, 2024

Magellan Rx Management, LLC earns URAC Accreditation in Health Utilization Management

Designation demonstrates highest level of commitment to quality health care